[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":603},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,43,0,25,[9,43,68,90,116,141,164,183,206,229,257,280,298,319,343,370,390,411,431,453,479,502,529,556,577],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100644371","phase-4-fuzheng-huayu-tablets-for-metabolic-dysfunction-associated-fatty-liver-cirrhosis-compensated-a-randomized-double-blind-placebo-controlled-multicenter-clinical-study-100644371",false,"NCT07663643","Fuzheng Huayu Tablets for Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study","Efficacy and Safety of Fuzheng Huayu Tablets in Patients With Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study","Inclusion Criteria:\n\n1. Aged 18 to 75 years (inclusive of both upper and lower limits).\n2. Diagnosed with compensated metabolic dysfunction-associated fatty liver cirrhosis, meeting all three of the following conditions:\n\n(1) At screening, FibroScan liver stiffness measurement (LSM) ≥ 20 kPa, OR LSM ≥ 15 kPa AND any one of the following: platelet count \\\u003C 150×10⁹\u002FL, or FIB-4 ≥ 3.48, or Agile4 ≥ 0.57; (2) Has a history of metabolic dysfunction or metabolic dysfunction-associated fatty liver disease (MAFLD); (3) Child-Turcotte-Pugh score \\\u003C 7 and MELD score \\\u003C 12. 3. Voluntarily participates in the clinical study and agrees to sign the informed consent form.\n\nExclusion Criteria:\n\n1. History or current hepatic decompensation events at screening, including but not limited to the following: a) Esophagogastric variceal bleeding; b) Hepatic ascites requiring diuretic treatment; c) Hepatic encephalopathy (West Haven grade 2 or above); d) Hepatorenal syndrome.\n2. Having a history or evidence of other chronic liver diseases, such as alcoholic liver disease, drug-induced liver disease, primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis or overlap syndrome, Wilson's disease, alpha-1 antitrypsin deficiency, hereditary hemochromatosis, history of biliary obstruction or biliary shunt, metastatic liver cancer; Hepatitis B (HBsAg positive); Hepatitis C (HCV antibody positive and HCV-RNA positive). Subjects with previous hepatitis C treatment must maintain negative HCV-RNA results for at least 3 years before screening to be eligible.\n3. History of liver transplantation, on the liver transplantation waiting list, or history of TIPS operation.\n4. Use of anti-obesity drugs within 3 months prior to screening and during the whole trial is prohibited, including bupropion-naltrexone, orlistat, phentermine, phentermine\u002Ftopiramate and anti-obesity supplements. Subjects planning to receive metabolic bariatric surgery during the study will be excluded (excluding acupuncture weight loss, liposuction or abdominal lipectomy performed more than 1 year before screening).\n5. Type 1 diabetes mellitus; uncontrolled type 2 diabetes mellitus, defined as HbA1c \\> 9% at screening or within 60 days before randomization. Subjects with HbA1c \\> 9% may be re-screened once no less than 3 months after the initial screening failure; insulin dosage adjustment more than 20% within 60 days before randomization is also excluded.\n6. Unstable use of drugs that may affect efficacy evaluation within 3 months prior to screening, including but not limited to Vitamin E (dose \\> 400 IU\u002Fd), thiazolidinediones (TZDs), SGLT-2 inhibitors, GLP-1 receptor agonists, and chiglitazar. Those who have taken stable dosage continuously until screening visit and will maintain relatively stable dosage throughout the study period are allowed to enroll.\n7. Use of drugs that may induce hepatic steatosis or steatohepatitis for at least 4 weeks within 6 months prior to screening (e.g., valproic acid, tamoxifen, methotrexate, amiodarone, long-term oral corticosteroids \\> 5 mg\u002Fd prednisone equivalent, or estrogen at doses higher than contraception or hormone replacement therapy). The above drugs are prohibited throughout the trial until the end of follow-up. Subjects requiring bronchodilators, topical, inhaled, nasal corticosteroids or caudal steroid injections are not excluded.\n8. Use of Chinese herbal medicine and proprietary Chinese medicines with anti-fibrotic or MAFLD therapeutic effects within 3 months prior to screening, including but not limited to Compound Biejia Ruangan Capsules, Anluo Huaxian Pills, Qianggan Capsules\u002FTablets. If the medication course is no more than 3 months, subjects can be enrolled after a 1-month washout period.\n9. Uncontrolled hypertension at screening, defined as systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg.\n10. Occurrence of myocardial infarction, unstable angina, malignant arrhythmia, percutaneous coronary intervention, coronary artery bypass grafting, ischemic or hemorrhagic stroke, transient ischemic attack, acute peripheral vascular events within 6 months prior to screening.\n11. Active severe diseases or malignant tumors with a life expectancy of less than 5 years.\n12. Uncontrolled hypothyroidism or hyperthyroidism at screening (assessed by the investigator). Participants with hypothyroidism receiving stable-dose thyroid hormone replacement therapy for at least 2 months before screening can be enrolled.\n13. Abnormal laboratory indicators at screening: ALT \\> 5 × ULN, AST \\> 5 × ULN, ALP ≥ 2 × ULN (unless ALP elevation is non-hepatic origin), eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m², INR \\> 1.5 × ULN, total bilirubin \\> 1.5 × ULN (for participants with Gilbert syndrome, TBIL threshold ≥ 3 × ULN), ALB \\\u003C 28 g\u002FL.\n14. Thrombocytopenia caused by hematological diseases such as immune thrombocytopenic purpura, drug influence or active infection.\n15. Female subjects who are pregnant, breastfeeding or planning to become pregnant during the trial.\n16. Allergy to the investigational drug or its ingredients.\n17. Subjects who are expected to be unable to comply with the study protocol or fail to complete the trial as planned.","ALL","18 Years","75 Years",{"count":21,"type":22},459,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This is a multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of Fuzheng Huayu Tablets in patients with metabolic dysfunction-associated fatty liver cirrhosis (compensated). Eligible patients will be randomly assigned to receive either Fuzheng Huayu Tablets or placebo for 72 weeks. The primary objective is to assess the improvement in liver fibrosis, measured by liver stiffness reduction via FibroScan. Secondary objectives include changes in liver function indicators, liver fibrosis markers, Child-Pugh score, and safety profile.",[28],"Metabolic Dysfunction-associated Fatty Liver Cirrhosis",[30],"Metabolic dysfunction-associated fatty liver cirrhosis","NOT_YET_RECRUITING","2026-06-17",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":22},"2026-05-25",{"date":39,"type":22},"2029-04-02",{"name":41,"class":42},"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100639007","transcranial-temporal-interference-stimulation-for-children-with-autism-spectrum-disorders-100639007","NCT07625748","Transcranial Temporal Interference Stimulation for Children With Autism Spectrum Disorders","Individualized Targeted Transcranial Temporal Interference Stimulation for Children With Autism Spectrum Disorder: A Single-Blinded, Randomized, Controlled Exploratory Trial","Inclusion Criteria:\n\n* Children aged 4-10 years\n* Meeting the diagnostic criteria for ASD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and confirmed by the Autism Diagnostic Observation Schedule (ADOS) and\u002For the Autism Diagnostic Interview-Revised (ADI-R)\n* Full Scale Intelligence Quotient (FSIQ) ≥50\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Individuals with metal implants in the body\n* Individuals with neurological disorders such as epilepsy\n* Those requiring surgical treatment due to structural abnormalities indicated by brain MRI examination\n* Those diagnosed with genetic or chromosomal abnormalities\n* Individuals with mental illness (such as early-onset schizophrenia)\n* Those with severe cardiac disease\n* Individuals with increased intracranial pressure\n* Those currently participating in other clinical trials\n* Those who received new intervention protocols within 4 weeks prior to enrollment.","4 Years","10 Years",{"count":53,"type":22},16,[55],"NA","The goal of this single-blinded, randomized controlled trial is to assess the safety, tolerability, and feasibility of tTIS for children with ASD. The main question it aims to answer is:\n\n\\- Is tTIS safe, tolerable, and feasible for use for children with autism spectrum disorder?\n\nResearchers will compare tTIS group with control group to explore the safety and feasibility of the transcranial electrical stimulation for children with autism.\n\nParticipants will:\n\n* tTIS group: undergo 5 days of temporal tTIS.\n* Sham group: undergo 5 days of temporal tTIS without low-frequency envelope.\n\nFrom baseline to 4 weeks after intervention completion, subjects will be followed up regarding clinical symptoms and adverse events:\n\n* Primary Outcome Measures: Safety and feasibility of tTIS, assessed by adverse events, treatment completion rate, adherence to the stimulation protocol and tolerability.\n* Secondary\u002FExploratory Outcome Measures: Changes in SRS-2 total scores and other clinical measures related to language, adaptive functioning, and cognition.",[58],"Autism Spectrum Disorder","RECRUITING","2026-05-29",{"date":62,"type":35},"2026-06-04",{"date":37,"type":22},{"date":65,"type":22},"2026-10-05",{"name":41,"class":42},1,{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":17,"minAge":50,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100629250","a-study-on-the-efficacy-and-user-experience-of-gamified-intervention-for-children-with-anisometropic-amblyopia-100629250","NCT07472231","A Study on the Efficacy and User Experience of Gamified Intervention for Children With Anisometropic Amblyopia","An Exploratory Study on the Short-Term Additive Efficacy and User Experience of Innovative Gamified Intervention as an Adjunctive Therapy for Children With Monocular Anisometropic Amblyopia","Inclusion Criteria:\n\n1. Clinically diagnosed with monocular anisometropic amblyopia.\n2. Aged 4 to 7 years.\n3. Able to cooperate with all examinations and comply with the amblyopia training regimen.\n4. Provided signed informed consent.\n\nExclusion Criteria:\n\n1. Severe developmental delay or cognitive impairment.\n2. Serious systemic diseases.\n3. Presence of organic ocular diseases (e.g., cataract, fundus diseases) or manifest strabismus.\n4. Participation in any other eye-related interventional trial within the past 4 weeks.","7 Years",{"count":77,"type":22},66,[55],"This project addresses the challenge of visual function intervention in children with monocular anisometropic amblyopia. It employs two innovatively designed digital games combined with occlusion therapy to conduct visual function training through parent-child interaction in home or multi-scenario environments. The study will compare this combined approach against traditional occlusion therapy alone, evaluating improvements in visual function, intrinsic motivation, and emotion regulation before and after the intervention. The research aims to promote the implementation and dissemination of personalized and engaging healthcare services. Ultimately, it seeks to establish a comprehensive visual function training product and service system suitable for daily use in home settings, with the goals of reducing medical anxiety in children and holistically enhancing treatment efficacy, training compliance, and overall clinical experience.",[81],"Amblyopia","2026-04-23",{"date":84,"type":35},"2026-04-29",{"date":86,"type":22},"2026-05",{"date":88,"type":22},"2026-12",{"name":41,"class":42},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":75,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":67},"100635455","a-random-controlled-trial-of-home-based-digital-therapy-for-treating-adhd-in-children-100635455","NCT07552909","A Random Controlled Trial of Home-based Digital Therapy for Treating ADHD in Children","Randomized Controlled Study on Home-Based Digital Therapy Intervention for School-Aged Children With Attention Deficit Hyperactivity Disorder Based on Brain-Controlled Games","Inclusion Criteria:\n\n* Children aged 7 years 0 months to 11 years 11 months\n* Clinical diagnosis of ADHD made by a child psychiatrist at the attending level or above\n* Wechsler Intelligence Scale for Children (WISC) Full Scale IQ (FSIQ) above 85\n* Children who have been diagnosed with ADHD but have not received any intervention (newly diagnosed within the last month or not having taken medication for at least 4 weeks)\n* Informed consent must be obtained from the patient\u002Fguardian and from participants\n\nExclusion Criteria:\n\n* Auditory or visual illness or disorder\n* Inability to use software (e.g., color blindness, impaired hand function, or disability)\n* Comorbid oppositional defiant disorder, autism spectrum disorder, pervasive developmental disorder, tic disorders, or other neurodevelopmental disorders\n* Other mental illnesses such as organic mental disorders, schizophrenia, bipolar disorder, or depressive disorders\n* Attention deficit disorder caused by organic neurological diseases or other organic diseases\n* Previous regular ADHD medication use as prescribed by a doctor, but without efficacy\n* Past or present gaming addiction\n* Previous neurofeedback-like \"brain control game\" interventions\n* Previous physical therapy such as magnetic stimulation.","11 Years",{"count":99,"type":22},146,[55],"Explore the interventional effects of neurofeedback games on school-aged children with mild to moderate ADHD, with the aim of providing evidence-based new methods for intervening in the core symptoms of ADHD in children.",[103],"Attention Deficit Hyperactivity Disorder (ADHD)",[105,106,107],"Attention deficit hyperactivity disorder","Randomized Controlled","Digital Brain-controlled","2026-04-22",{"date":110,"type":35},"2026-04-27",{"date":112,"type":35},"2025-08-24",{"date":114,"type":22},"2026-05-31",{"name":41,"class":42},{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":12,"sex":122,"minAge":18,"maxAge":123,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":67},"100455141","comparison-of-the-therapeutic-effects-of-vaginal-repair-with-leuprorelin-and-vaginal-repair-in-the-treatment-of-cesarean-section-scar-defect-100455141","NCT05206682","Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect","Inclusion Criteria:\n\n1. Clearly diagnosed with CSD complicated with adenomyosis\n2. Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 10 days).\n3. The thickness of the remaining muscular layer of CSD was less than 3 mm.\n4. Normal range of blood sugar and insulin\n5. No serious medical problems (important viscera function in the normal range).\n6. uterine fibroids no more than 5cm\n7. Sign the informed consent.\n\nExclusion Criteria:\n\n1. Indefinite diagnosis.\n2. Malignant tumors.\n3. With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs).\n4. Pregnant.\n5. Mental diseases.\n6. Allergy to the any ingredients of Leuprorelin\n7. Unwilling to comply with the research plan.","FEMALE","50 Years",{"count":125,"type":22},94,[55],"GnRH-a will be used to postpone period after vaginal repair for Cesarean Section Scar Defect（CSD） patients with adenomyosis which will be compared with CSD patients with adenomyosis who receive transvaginal surgery without GnRH-a, whether delayed period improving the CSD prognosis will be assessed.",[129],"Cesarean Section; Dehiscence",[131,132,133],"Cesarean Section Scar Defect","Zoladex","vaginal repair",{"date":135,"type":35},"2026-04-24",{"date":137,"type":35},"2023-05-01",{"date":139,"type":22},"2027-12-30",{"name":41,"class":42},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":122,"minAge":18,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":67},"100455036","comparison-of-the-therapeutic-effects-of-vr-and-vr--metformin-in-the-treatment-of-cesarean-section-scar-defect-100455036","NCT05205317","Comparison of the Therapeutic Effects of VR and VR + Metformin in the Treatment of Cesarean Section Scar Defect","Comparison of the Therapeutic Effects of Vaginal Repair and Vaginal Repair + Metformin in the Treatment of Cesarean Section Scar Defect","Inclusion Criteria:\n\n1. Patients are younger than 40 and over the age of 18.\n2. Clearly diagnosed with CSD.\n3. Experiencing clinical features of abnormal uterine bleeding, prolonged menstrual flow (the duration of menstruation is more than 10 days).\n4. The thickness of the remaining muscular layer of CSD was less than 3 mm.\n5. Normal range of blood sugar and insulin\n6. No serious medical problems (important viscera function in the normal range).\n7. No uterine fibroids, endometriosis, adenomyosis\n8. No malignant tumors.\n9. Sign the informed consent.\n\nExclusion Criteria:\n\n1. Over the age of 40 or younger than 18;\n2. Indefinite diagnosis.\n3. Malignant tumors.\n4. With severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs).\n5. Contraindications to metformin (baseline creatinine \\>124μmol\u002FL, hypersensitivity to metformin, or a metabolic acidosis), use of drugs that might interact with metformin (glyburide, furosemide, or cationic drugs)\n6. Pregnant.\n7. Mental diseases.\n8. Unwilling to comply with the research plan.","40 Years",{"count":150,"type":22},100,[55],"Cesarean section scar defect (CSD) is a novel recognized cause of postmenstrual abnormal uterine bleeding in women. No clinical guidelines have been issued for the management of CSD. The investigators have previously demonstrated that vaginal repair of CSD was an relative effective treatment of CSD. However, only 28.2% of the CSD patients normalized to less than 7 days of menstruation, whereas 51.2% of women had 7 to 10 days of menstruation at 6 months post vaginal repair. The previous research suggested that the occurrence of CSD may be related to the aging phenotype of the myometrium. Metformin, as a classic diabetes treatment drug, has an important position in anti-aging therapy. Therefore, the randomized study was designed to evaluate whether the application of metformin in combination with vaginal repair could achieve better clinical effects than those achieved by vaginal CSD repair alone.",[154],"Defect",[156,157],"cesarean section scar defect","metformin",{"date":135,"type":35},{"date":160,"type":35},"2023-04-15",{"date":162,"type":22},"2027-06-30",{"name":41,"class":42},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":122,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":67},"100441397","ctdna-as-a-novel-biomarker-of-treatment-efficacy-in-patients-with-ovarian-cancer-100441397","NCT05027828","CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer","Circulating Tumor DNA as a Novel Molecular Marker of Treatment Efficacy to Guide Targeted Maintenance Therapy for Patients With High Grade Serous Ovarian Cancer","Inclusion Criteria:\n\n1. Ovarian cancer first diagnosed and treated;\n2. Pathologically confirmed as epithelial ovarian cancer\u002Ffallopian tube cancer\u002Fprimary peritoneal cancer;\n3. The stage of the disease is II-IV, and surgery will be performed after evaluation;\n4. Age ≥ 18 years old;\n5. Subjects and their families fully understand the research plan and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Pathologically confirmed as non-epithelial ovarian cancer;\n2. Surgical treatment cannot be performed after evaluation;\n3. Malignant tumors found in other parts of the study were found within five years before enrollment or at the time of enrollment;\n4. Patients who do not agree to use clinical first-line targeted drugs;\n5. Severe mental illness;\n6. Severe cardiovascular disease, uncontrollable infection, or other uncontrollable comorbid diseases.",{"count":150,"type":22},"OBSERVATIONAL","This study is a prospective observational clinical trial. Patients who were diagnosed and treated for the first time were enrolled and their surgical pathology was confirmed to be high-grade serous ovarian cancer. At the same time, these patients will receive first-line maintenance treatment with PARP inhibitors after traditional chemotherapy. During the trial period, patients' plasma will be collected before surgery, after chemotherapy, during targeted maintenance therapy, and during disease progression, and ctDNA-specific genomes will be detected, and clinical data will be collected over the same period. It is expected that specific ctDNA can be used to predict the efficacy of PARP inhibitors in patients with ovarian cancer, and to detect the recurrence of the disease early.",[175,176],"High-grade Serous Ovarian Cancer","Circulating Tumor DNA",{"date":135,"type":35},{"date":179,"type":35},"2021-09-01",{"date":181,"type":22},"2027-09-30",{"name":41,"class":42},{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":12,"sex":17,"minAge":148,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":196,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":205,"locationsCount":67},"100285237","99tc-mdp-treatment-for-knee-osteoarthritis-100285237","NCT02993029","99Tc-MDP Treatment for Knee Osteoarthritis","99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n1. Participants with painful osteoarthritis;\n2. The standard uptake value (SUV) of OA related knee greater than 10 on 18F- sodium fluoride bone scan;\n3. Participants voluntarily participate in the trial, and signed the informed consent.\n\nExclusion Criteria:\n\n1. Knee joint replacement;\n2. Inflammatory arthritis or joint infection of knee;\n3. Nervous joint disease;\n4. Fracture of joint;\n5. Gout arthritis of the knee;\n6. Traumatic arthritis.",{"count":191,"type":22},40,[55],"Osteoarthritis (OA) of knee is the most common form of arthritis in the world1e, and it has received growing attention in the society because of the increase of old age population, disabled people, and medical expenses from this disease. 99Tc-MDP is effective for rheumatoid arthritis. Therefore, the investigators try to investigate the effects of 99Tc-MDP treatment in patients with osteoarthritis of knee as compared with celecoxib.",[195],"Treatment Outcome",[197,198,199],"99Tc-MDP","osteoarthritis","celecoxib",{"date":201,"type":35},"2026-04-28",{"date":203,"type":35},"2017-09-01",{"date":139,"type":22},{"name":41,"class":42},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":213,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":67},"100621821","a-multimodal-ai-prediction-model-for-complications-after-transcatheter-closure-of-perimembranous-vsd-in-children-100621821","NCT07375602","A Multimodal AI Prediction Model for Complications After Transcatheter Closure of Perimembranous VSD in Children","Multimodal Clinical Data Integration and Artificial Intelligence Modeling for Predicting Complications Following Pediatric Transcatheter Closure of Perimembranous Ventricular Septal Defect","Inclusion Criteria:\n\n* Age ≤ 18 years at the time of transcatheter procedure.\n* Diagnosis of perimembranous ventricular septal defect confirmed by echocardiography, and underwent transcatheter device closure at the study center.\n* Medical records sufficient to ascertain the primary outcome within the pre-specified follow-up window, and availability of minimum baseline clinical information required for model development\u002Fvalidation.\n\nExclusion Criteria:\n\n* Ventricular septal defects not classified as perimembranous on echocardiography, including muscular, outlet, or inlet VSDs, as well as multiple or complex VSDs involving more than one septal region.\n* Presence of complex congenital heart disease or associated structural abnormalities requiring concomitant surgical repair (e.g., tetralogy of Fallot).\n* Prior surgical VSD repair or prior transcatheter VSD closure.",{"count":214,"type":22},5249,"The goal of this observational study is to develop and validate a multimodal artificial intelligence prediction model for treatment-related complications in children with perimembranous ventricular septal defect (pmVSD) undergoing transcatheter device closure. The main question it aims to answer is: Can an AI model that integrates demographics, laboratory results, electronic health record text, echocardiography reports, chest radiographs, and electrocardiogram accurately predict the risk of complications at the individual patient level? Data will be retrospectively collected from routine clinical care records of pediatric patients who underwent transcatheter closure for pmVSD. Deep learning methods will be used to extract features from text and images to train and validate the prediction model.",[217,218,219,220],"Congenital Heart Disease (CHD)","Ventricular Septal Defects (VSD)","Cardiac Catheterization","Postoperative Complications","2026-04-03",{"date":223,"type":35},"2026-04-09",{"date":225,"type":35},"2026-02-01",{"date":227,"type":22},"2026-06-15",{"name":41,"class":42},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":23,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":67},"100631909","effects-of-different-music-tempos-on-feeding-outcomes-in-preterm-infants-100631909","NCT07506811","Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants","Effects of Different Music Tempos on Feeding Outcomes in Preterm Infants: a Randomized Open-label Parallel-controlled Trial Protocol","Inclusion Criteria:\n\n* Preterm infants of gestational age ≥32 weeks or corrected gestational age ≥32 weeks\n* Admitted to hospital within 24 hours after birth\n* Apgar score ≥8 points\n* Normal auditory function according to examination of brainstem auditory evoked potential\n\nExclusion Criteria:\n\n* Congenital system defects including congenital heart disease, nervous system malformations, diaphragmatic hernias, gastrointestinal malformations\n* Serious complications, such as intracranial hemorrhage, respiratory failure, or serious infection, and those requiring mechanical ventilation","32 Weeks","37 Weeks",{"count":239,"type":22},284,[55],"Background Newborns perceive the world through sound, and music therapy in the neonatal intensive care unit has been shown to have significant benefits in terms of heart rate, oxygen saturation, sucking\u002Ffeeding capacity, and length of hospital stay. However, it is still unclear what kind of music therapy can better promote early extrauterine growth in preterm infants, and further exploration and practice are needed. Music therapy is an emerging interdisciplinary discipline that integrates musicology, medicine, and psychology. In the uterine environment, the most important rhythmic sounds that the fetus can hear is the mother's heartbeat, as well as the fetus's own heartbeat. The maternal heart rate ranges from 60 to 100 beats\u002Fmin, and the corresponding speed of 60-100 beats\u002Fmin in music is medium speed. The fetal heart rate is 110-160 beats\u002Fmin, and the corresponding speed of 110-160 beats\u002Fmin in music is considered fast. Music slower than 40-50 beats\u002Fmin is slow. The primary objective of this study is to investigate the effect of music therapy at different music speeds in preterm infants, at the time to full enteral feeding.\n\nMethods This is a single-center, randomized, open-label, parallel-controlled trial including 284 preterm newborns with gestational age or corrected gestational age ≥32 weeks admitted into the neonatal intensive care unit. The infants will be randomly allocated to receive music I, II, III or control therapy. The music therapy is provided with the same music in three different tempos: 40-50 beats\u002Fmin, 60-100 beats\u002Fmin, and 110-160 beats\u002Fmin, by two professional licensed music therapists using the same instrument and singing, before morning and afternoon feeding time every day during hospitalization. The primary outcome is the time to achieving full enteral feeding. The secondary outcomes include sucking\u002Ffeeding capacity, physical growth rate, complications, length of hospital stay, behavior state (Test of Infant Motor Performance (TIMP), Bayley III Infant Development Scale), and brain imaging (resting functional magnetic resonance imaging).\n\nHypothesis:\n\nThe investigator expect that either music therapy applied at 40-50 beats\u002Fmin or 110-160 beats\u002Fmin will result in early full enteral feeding, and reductions in length of hospital stay and complications in preterm infants.",[243],"Music",[245,246,247,248],"preterm infant","feeding","Music therapy","music speed","2026-03-28",{"date":251,"type":35},"2026-04-02",{"date":253,"type":22},"2026-09-20",{"date":255,"type":22},"2029-07-31",{"name":41,"class":42},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":122,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":268,"studyType":172,"phases":4,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":67},"100629366","ai-based-ultrasound-prediction-of-pregnancy-outcomes-in-placental-related-fetal-growth-restriction-mvm-fgr-a-prospective-cohort-study-100629366","NCT07473739","AI-Based Ultrasound Prediction of Pregnancy Outcomes in Placental-Related Fetal Growth Restriction (MVM-FGR): A Prospective Cohort Study","Establishment of a Cohort of Maternal Vascular Malperfusion-Related Fetal Growth Restriction (MVM-FGR) Based on an Etiology-Oriented Diagnostic Pathway: Artificial Intelligence-Assisted Multiparametric Ultrasound Prediction of Pregnancy Outcomes","Inclusion Criteria:\n\n* Singleton pregnancy.\n* Isolated early-onset placental insufficiency-related fetal growth restriction (FGR), with priority given to cases with abnormal umbilical artery Doppler flow.\n* Pregnancies in which expectant management is continued.\n\nExclusion Criteria:\n\n* Multiple pregnancy complicated by selective fetal growth restriction (sFGR).\n* FGR caused by fetal structural anomalies, genetic abnormalities, or intrauterine infection.\n* Twin pregnancy with intrauterine fetal demise (IUFD) of one fetus.","20 Years","43 Years",{"count":267,"type":22},300,"2 Years","The goal of this prospective cohort study is to enroll pregnancies complicated by placental-related fetal growth restriction (FGR) and to develop predictive models for adverse short- and long-term outcomes. This will be achieved by collecting novel intrauterine monitoring indicators along the fetal brain-placenta-heart axis, combined with conventional fetal surveillance parameters, in order to improve risk stratification and guide clinical management, ultimately improving pregnancy outcomes.\n\nThe study will include pregnant women with singleton pregnancies complicated by isolated early-onset placental insufficiency-related FGR, preferably those with abnormal umbilical artery Doppler findings, who elect to continue the pregnancy.\n\nThe main question it aims to answer is:\n\n• Whether a predictive model integrating novel intrauterine monitoring indicators along the fetal brain-placenta-heart axis with conventional monitoring parameters can accurately predict perinatal and neonatal adverse outcomes in pregnancies complicated by placental-related FGR.",[271],"Fetal Growth Restriction (FGR)","2026-03-11",{"date":274,"type":35},"2026-03-16",{"date":276,"type":35},"2023-01-01",{"date":278,"type":22},"2028-11-30",{"name":41,"class":42},{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":148,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":297,"locationsCount":67},"100320345","predicting-risk-factors-for-exacerbation-of-chronic-obstructive-pulmonary-disease-100320345","NCT03450603","Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease","It is Crucial to Identify Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease in Order to Provide Adequate Intensive Therapy and Closer Follow-up","Inclusion Criteria:\n\n* Clinical diagnosis of Chronic obstructive pulmonary disease\n* aged \\>= 40 years\n\nExclusion Criteria:\n\n* spirometry can not be completed because of various reasons\n* asthma\n* pulmonary embolism\n* lung cancer\n* sequelae of tuberculosis\n* extensive bronchiectasis\n* interstitial lung disease\n* left cardiac insufficiency",{"count":288,"type":22},200,"Exacerbations of chronic obstructive pulmonary disease (COPD) are unfavourable events in the course of disease for most COPD patients. Published evidence indicates a significant impact of exacerbations, especially if frequent, on patients' health-related quality of life (HRQL), disease progression, mortality, health care utilisation and costs. However, the severity,evolution and outcome of an exacerbation may differ significantly between patients - some patients will recover completely in a short period of time while others may die. The identification of risk factors for an adverse outcome could help in distinguishing patients who require more intense management in order to prevent failures, achieve satisfactory recovery and reduce the negative clinical and socioeconomic impact of exacerbations.The pathogenesis of COPD is still unclear, so there is no specific treatment at present .COPD was considered to be the result of a combination of environmental and genetic factors. Genetic factors play an important role in the acute exacerbation of COPD.Therefore, it is an urgent need to explore the heterogeneity of COPD phenotype from the perspective of genes and to seek individualized prevention and treatment programs.This study is intended to provide a theoretical basis for the prevention, evaluation and development of individualized treatment plans for acute exacerbation of COPD, thereby improving the prognosis of the disease.",[291],"Chronic Obstructive Pulmonary Disease","2026-03-09",{"date":272,"type":35},{"date":295,"type":35},"2017-12-10",{"date":139,"type":22},{"name":41,"class":42},{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100626865","efficacy-and-safety-of-henagliflozin-retagliptin-and-metformin-extended-release-tablets-in-chinese-patients-with-type-2-diabetes-mellitus-100626865","NCT07441187","Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n1. Male or female aged 18 to 70 years (inclusive) at the time of signing the informed consent form.\n2. Diagnosed with type 2 diabetes mellitus.\n3. Voluntarily participate in this study and sign the informed consent form. If a subject is unable to read the informed consent form (e.g., an illiterate subject), an impartial witness must be present during the entire informed consent discussion and must also sign the consent form.\n4. At screening, the subject must meet either of the following two criteria:\n\n   1. Newly diagnosed with type 2 diabetes within 90 days prior to screening, with no prior use of any antidiabetic medication, and a screening HbA1c level between 8.0% and 11.0% (inclusive).\n   2. Treated with any one oral antidiabetic drug \\[metformin (with a stable daily dose ≥1000 mg or the maximum tolerated dose documented in the patient's medical record), an alpha-glucosidase inhibitor, a sulfonylurea, a glinide, a thiazolidinedione, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), a dipeptidyl peptidase-4 inhibitor (DPP-4i), a glucokinase activator, or an oral glucagon-like peptide-1 receptor agonist\\] for at least 60 days prior to screening, with a screening HbA1c level between 7.0% and 11.0% (inclusive). The subject should have been on a stable dose of the medication for at least 30 days prior to screening.\n5. Body Mass Index (BMI) \\>19 kg\u002Fm² and ≤40.0 kg\u002Fm².\n\nExclusion Criteria\n\n1. Type 1 diabetes mellitus, monogenic diabetes, diabetes due to pancreatic injury, or other forms of secondary diabetes (e.g., diabetes secondary to Cushing's syndrome or acromegaly).\n2. Fasting C-peptide \\\u003C1.0 ng\u002FmL (0.34 nmol\u002FL) as measured by the local laboratory.\n3. Known or suspected hypersensitivity to the investigational product or related compounds.\n4. Participation in any other investigational drug trial within 3 months prior to the start of this study.\n5. Use of traditional Chinese herbal medicine for glycemic control within 2 months prior to screening (except for cumulative use ≤7 days).\n6. History of acute metabolic complications (e.g., ketoacidosis, lactic acidosis, hyperosmolar coma\u002Fstate) within the past 6 months.\n7. History of decompensated heart failure (NYHA Class IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, or cardiac surgery or vascular reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) within the past 6 months.\n8. Severe infection, significant trauma, or major surgery within 30 days prior to screening.\n9. History of acute or chronic pancreatitis.\n10. Patients with malignancy and a life expectancy of less than one year, active tuberculosis, or acute infection.\n11. Current or history of recurrent urinary tract infections and\u002For genital infections.\n12. Patients with a history of hypertension whose blood pressure remains uncontrolled despite antihypertensive medication: systolic blood pressure (SBP) \\>180 mmHg and\u002For diastolic blood pressure (DBP) \\>110 mmHg.\n13. Systolic blood pressure \\\u003C90 mmHg at the screening visit, or patients judged by the clinician to be hypovolemic.\n14. Moderate to severe renal impairment (eGFR \\\u003C45 mL\u002Fmin\u002F1.73m²), end-stage renal disease, or patients on dialysis.\n15. Men or women of childbearing potential unwilling to use effective contraception during the trial, or women who are pregnant or breastfeeding.\n16. Alanine aminotransferase (ALT) \\>3.0 x ULN and\u002For aspartate aminotransferase (AST) \\>3.0 x ULN and\u002For total bilirubin \\>2.0 x ULN (upper limit of normal).\n17. Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in this clinical trial.","70 Years",{"count":267,"type":22},"Given the significant and growing burden of Type 2 Diabetes (T2DM) in China, there is a continuous need for effective, convenient, and well-tolerated treatment strategies. This Phase IV, multicenter, prospective, observational study aims to evaluate the real-world effectiveness and safety of a novel, once-daily, fixed-dose combination (FDC) tablet containing Henagliflozin (SGLT2 inhibitor), Retagliptin (DPP-4 inhibitor), and Metformin Extended-Release in Chinese patients with T2DM. The study plans to enroll approximately 300 patients across 30 sites, stratified into two cohorts: newly diagnosed, drug-naïve patients and those with inadequate glycemic control on a single prior oral antidiabetic drug. The primary objective is to assess the change in Glycated Hemoglobin (HbA1c) from baseline after 24 weeks of treatment. Key secondary objectives include evaluating the proportion of patients achieving HbA1c targets (\\\u003C7.0% and ≤6.5%), assessing changes in other metabolic parameters such as body weight, blood pressure, fasting and postprandial glucose, and lipid profiles, and monitoring treatment adherence. The safety evaluation will comprehensively document all adverse events, with special attention to events of interest including hypoglycemia, urinary\u002Fgenital infections, volume-related events, and diabetic ketoacidosis. The study design includes a screening period, a 2-week run-in with lifestyle intervention, a 24-week core treatment period where eligible patients receive the FDC therapy, and a final safety follow-up. Efficacy and safety assessments are scheduled at baseline, Week 4, Week 12, and Week 24. Statistical analysis will be primarily descriptive, focusing on changes from baseline for continuous endpoints and frequency distributions for categorical endpoints, with analyses conducted separately for the two patient cohorts. The study will be conducted in full compliance with Good Clinical Practice (GCP), the Declaration of Helsinki, and relevant Chinese regulations, requiring prior ethics committee approval and written informed consent from all participants. This real-world evidence study seeks to confirm the clinical benefits and safety profile of this triple-combination therapy observed in earlier controlled trials, providing practical insights into its use in routine management of T2DM within the Chinese healthcare context.",[308],"T2DM (Type 2 Diabetes Mellitus)",[310],"SGLT2 inhibitor","2026-02-23",{"date":313,"type":35},"2026-02-27",{"date":315,"type":22},"2026-02-20",{"date":317,"type":22},"2027-12-31",{"name":41,"class":42},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":325,"sex":17,"minAge":326,"maxAge":18,"enrollmentInfo":327,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":329,"conditions":330,"keywords":334,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":341,"leadSponsor":342,"locationsCount":67},"100624132","clinical-study-on-an-artificial-intelligence-assisted-chest-radiograph-model-based-on-big-data-and-deep-learning-for-early-detection-of-kawasaki-disease-100624132","NCT07405658","Clinical Study on an Artificial Intelligence-Assisted Chest Radiograph Model Based on Big Data and Deep Learning for Early Detection of Kawasaki Disease","Inclusion Criteria:\n\n1. Case group\n\n   * The age of seeking medical treatment is less than or equal to 18 years old; ·The medical record system diagnosis contains the diagnosis of \"Kawasaki Disease\", \"mucocutaneous lymph node syndrome\" or \"IVIG non-response Kawasaki disease\"\n   * At least one complete chest X-ray examination data (images and reports) is available during the same hospitalization\n2. Control group\n\n   * The age of seeking medical treatment is less than or equal to 18 years old\n   * The same period as the case group\n   * Fever lasts for 3 days or more\n   * Rule out the possibility of diagnosing Kawasaki disease\n\nExclusion Criteria:\n\n1. Case group\n\n   * Chest X-ray quality issues: Severe artifacts, overexposure\u002Funderexposure leading to inability to assess key structures\n   * Incomplete clinical information, including lack of chest X-ray examination, laboratory tests, and unclear days of fever Inability to determine the final diagnosis (such as loss to follow-up, diagnosis in doubt)\n2. Control group\n\n   * Chest X-ray quality issues: Severe artifacts, overexposure\u002Funderexposure leading to inability to assess key structures\n   * Incomplete clinical information, including lack of chest X-ray examination, laboratory tests, and unclear days of fever\n   * Inability to make a clear final diagnosis (such as loss to follow-up, questionable diagnosis)",true,"0 Years",{"count":328,"type":22},20000,"The goal of this observational study is to develop an AI-based early warning system for Kawasaki Disease (KD) using chest X-rays (CXR) in children diagnosed with Kawasaki Disease. The main question\\[s\\] it aims to answer are:\n\n1. Can AI modeling of CXR features help identify high-risk KD patients earlier than current diagnostic methods?\n2. Can the AI system predict the optimal IVIG treatment window and coronary artery risks in KD patients?\n\nParticipants will:\n\nProvide retrospective data on chest X-rays and clinical data (CRP, coronary ultrasound, etc.) Allow analysis of CXR features using deep learning models to extract relevant patterns Have their data incorporated into a federated learning model to ensure privacy and data security",[331,332,333],"Kawasaki Disease","Chest X-ray for Clinical Evaluation","Mucocutaneous Lymph Node Syndrome",[331,335,336],"Artificial Intelligence","Mucocutaneous lymph node syndrome","2026-02-10",{"date":339,"type":35},"2026-02-12",{"date":225,"type":22},{"date":317,"type":22},{"name":41,"class":42},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":4,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":352,"briefSummary":354,"conditions":355,"keywords":357,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":367,"leadSponsor":369,"locationsCount":4},"100622267","phase-2-neoadjuvant-mfolfox6-chemotherapy-combined-with-anti-pd-1-therapy-in-msspmmr-locally-advanced-rectal-cancer-firm02-study-100622267","NCT07381400","Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS\u002FpMMR Locally Advanced Rectal Cancer (FIRM02 Study)","A Multicenter, Randomized Controlled Clinical Study of Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS\u002FpMMR Locally Advanced Rectal Cancer (FIRM02 Study)","Inclusion Criteria:\n\n1. Rectal cancer patients with MRI showing the lower edge of the tumor within 15 cm of the anal verge, cT3-4 N any or cT any N1\u002F2;\n2. Pathologically confirmed adenocarcinoma, with pMMR (MLH1, MSH2, MSH6, and PMS2) positivity for all four proteins, or gene testing indicating microsatellite stability;\n3. No complete bowel obstruction, or proximal colostomy relieving bowel obstruction;\n4. Aged 18 to 75 years, regardless of gender;\n5. ECOG performance status: 0-1;\n6. Expected survival time ≥2 years;\n7. No previous chemotherapy, radiotherapy, targeted therapy, or immunotherapy;\n8. Laboratory test results meeting the following criteria during screening:Hematology: Neutrophil count ≥1.5×10⁹\u002FL, platelet count ≥75×10⁹\u002FL, hemoglobin ≥80 g\u002FL; Liver function: AST and ALT ≤2.5× upper limit of normal (ULN); total bilirubin ≤1.5×ULN; Kidney function: Serum creatinine ≤1.5×ULN; Coagulation function: APTT ≤1.5×ULN, INR ≤1.5, PT ≤1.5×ULN; Urine protein: Urine protein ≤1+ (if ≥2+, 24-hour urine protein test required, and if result \\\u003C1g, inclusion is allowed); Cardiac left ventricular ejection fraction ≥50%;\n9. Female participants must not be breastfeeding, and pregnancy test results must be negative;\n10. Voluntary signing of the informed consent form, with the ability to understand and comply with the study requirements.\n\nExclusion Criteria:\n\n1. Local invasion of surrounding organs by rectal tumor: Imaging tests suggest the tumor directly invades adjacent organs or structures, i.e., tumors with clinical stage cT4 below the peritoneal reflection or cT4b above the peritoneal reflection;\n2. Patients with distant metastasis;\n3. Previous treatment with any chemotherapy, radiotherapy, targeted therapy, or immunotherapy;\n4. Active autoimmune diseases requiring systemic treatment (e.g., corticosteroids or immunosuppressants) within the past 2 years prior to enrollment;\n5. History of HIV infection, or active chronic hepatitis B or C (high viral DNA load);\n6. Currently receiving tuberculosis treatment or having received tuberculosis treatment in the past year prior to screening for active tuberculosis;\n7. Known or suspected allergy to the study drugs or any drug related to the study;\n8. Severe cardiovascular or cerebrovascular diseases;\n9. Severe active infection or uncontrollable infection requiring systemic treatment, or unexplained fever \\>38.5°C within 14 days before the first dose;\n10. Systemic corticosteroid treatment or other immunosuppressants within 14 days before the first dose, or immunostimulants within 4 weeks prior to the first dose;\n11. Clear history of neurological or psychiatric disorders, including epilepsy or dementia;\n12. Subjects who, for any other reason, may not be able to complete the study, or the investigator deems them unsuitable for inclusion;\n13. Refusal to sign the informed consent form.",{"count":351,"type":22},128,[353],"PHASE2","This multicenter, randomized controlled clinical trial (FIRM02 Study) aims to evaluate the effectiveness and safety of neoadjuvant mFOLFOX6 chemotherapy combined with PD-1 inhibitor (Serplulimab) in patients with MSS\u002FpMMR locally advanced rectal cancer (LARC). A total of 128 patients with non-metastatic, untreated, locally advanced rectal cancer will be randomly assigned in a 1:1 ratio to either the experimental group (64 patients) or the control group (64 patients). The experimental group will receive 6 cycles of mFOLFOX6 chemotherapy combined with 3 mg\u002Fkg of Serplulimab every 2 weeks prior to surgery. The control group will receive 6 cycles of mFOLFOX6 chemotherapy alone. The primary endpoint is the pathological complete response (pCR), and secondary endpoints include major pathological response (MPR), tumor regression grade (TRG), overall response rate (ORR), and survival outcomes (DFS, RFS, and OS). Safety will be assessed based on adverse events and post-operative complications.",[356],"Rectal Cancer",[358,359,360,361,362],"rectal cancer","PD1 inhibitor","pMMR","microsatellite stable","neoadjuvant therapy","2026-01-30",{"date":365,"type":35},"2026-02-03",{"date":225,"type":22},{"date":368,"type":22},"2031-12-31",{"name":41,"class":42},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":67},"100602791","multicenter-clinical-study-on-noninvasive-assessment-of-hepatic-steatosis-and-fibrosis-using-visual-transient-elastography-100602791","NCT07128108","Multicenter Clinical Study on Noninvasive Assessment of Hepatic Steatosis and Fibrosis Using Visual Transient Elastography","Inclusion Criteria:\n\n* Be aged 18-65 years.\n* Documented liver injury of any etiology with a liver biopsy performed within the past 2 weeks.\n* Willing to undergo Visual Transient Elastography (ViTE) examination using Mindray Hepatus 9 Ultrasound System and capable of providing written informed consent.\n\nExclusion Criteria:\n\n* Acute viral hepatitis.\n* Right heart failure with either:Serum transaminases \\>5× upper limit of normal (ULN),Total bilirubin \\>85.5 μmol\u002FL.\n* History of hepatocellular carcinoma (HCC).\n* Pregnancy.\n* Patients with implantable medical devices.","65 Years",{"count":378,"type":22},225,"Using liver biopsy as the gold standard, this study will conduct visual transient elastography (ViTE) examinations using Mindray Hepatus 9 ultrasound diagnostic system in patients with liver injury to evaluate the diagnostic efficacy of Liver Steatosis Analysis (LiSA) and ViTE for grading hepatic steatosis and fibrosis, and establish corresponding diagnostic thresholds.",[381,382],"Chronic Liver Injury","Mindray Hepatus 9 Ultrasound Diagnostic System","2025-11-21",{"date":385,"type":35},"2025-11-24",{"date":387,"type":35},"2025-08-14",{"date":317,"type":22},{"name":41,"class":42},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":67},"100604000","a-national-multicenter-survey-on-small-vulnerable-newborns-100604000","NCT07143825","A National Multicenter Survey on Small Vulnerable Newborns","A National Multicenter Epidemiological Investigation of Small Vulnerable Newborns in China","Inclusion Criteria:\n\n1. Newborns diagnosed as vulnerable infants at the participating hospitals between January 1 and December 31, 2024;\n2. Meeting any one of the following criteria:\n\n   * Diagnosed as small for gestational age (SGA): birth weight below the 10th percentile for infants of the same gestational age and sex;\n   * Preterm infants: gestational age less than 37 weeks;\n   * Low Birth Weight (LBW) infants: birth weight less than 2,500 grams.\n\nExclusion Criteria:\n\n* Incomplete medical records due to missing data preventing comprehensive case evaluation.",{"count":398,"type":22},2000,"The goal of this nationwide multicenter observational study is to comprehensively investigate the severity of Small Vulnerable Newborns (SVN) issues across China and to propose further preventive and intervention measures. The primary aim is to provide a thorough description of SVN problems using a unified definition and framework, and to develop targeted prevention strategies.\n\nParticipating centers across the country will collect clinical data on vulnerable newborns under their care and complete detailed questionnaires to support this research.",[401,402],"Preterm","Small Gestational Age (SGA)","2025-08-19",{"date":405,"type":35},"2025-08-27",{"date":407,"type":35},"2025-04-01",{"date":409,"type":22},"2026-12-31",{"name":41,"class":42},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":67},"100602885","rspo3sdc-1-pathway-dysfunction-in-alveolar-repair-after-ards-in-older-adults-100602885","NCT07129330","RSPO3\u002FSDC-1 Pathway Dysfunction in Alveolar Repair After ARDS in Older Adults","Role and Mechanisms of RSPO3\u002FSDC-1 Pathway Dysregulation in Impaired Alveolar Epithelial Repair Post-ARDS in Older Adults","Inclusion Criteria:\n\nClinical diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin Definition Age ≥ 65 years at enrollment First diagnosis of ARDS made within 24 hours prior to study entry Receiving either spontaneous (non-invasive) breathing support or invasive mechanical ventilation\n\nExclusion Criteria:\n\nCoexisting severe cardiac, hepatic or renal failure (NYHA Class III-IV) Active pulmonary infection (e.g. pneumonia or lung abscess) Significant coagulation disorders Receipt of any cytokine-based therapy within the past 3 months Participation in another interventional clinical study within the past 3 months",{"count":419,"type":22},1000,"Acute respiratory distress syndrome (ARDS) is a serious lung condition in which fluid builds up in the air sacs, making it hard to breathe and often requiring intensive care. Older adults fare worse because their lung-lining cells lose the ability to heal properly after injury This study will explore two key molecules-RSPO3 and Syndecan-1 (SDC-1)-that normally help alveolar (air-sac) cells regenerate. We will collect small blood samples from ARDS patients and, when patients undergo elective lung surgery, tiny pieces of healthy lung tissue. In the lab, we will also grow three-dimensional \"lung organoids\" from these samples to see how boosting or blocking RSPO3\u002FSDC-1 affects cell repair\n\nOur goals are to:\n\nMeasure RSPO3\u002FSDC-1 activity alongside inflammatory markers (e.g., IL-6, TNF-α) to understand their roles in age-related repair failure.\n\nBuild an integrated platform for early diagnosis, disease monitoring, and treatment evaluation in older ARDS patients.\n\nIdentify molecular targets that could lead to new therapies, helping older adults recover lung function more effectively.",[422,423],"Acute Respiratory Distress Syndrome (ARDS)","Age-related Impaired Alveolar Epithelial Repair","2025-08-12",{"date":403,"type":35},{"date":427,"type":22},"2025-09-01",{"date":429,"type":22},"2029-12-30",{"name":41,"class":42},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":325,"sex":17,"minAge":438,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":440,"conditions":441,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":67},"100602223","egr2-and-nlrp3-pathways-in-obstructive-sleep-apnea-related-cognitive-and-mood-disorders-100602223","NCT07120711","EGR2 and NLRP3 Pathways in Obstructive Sleep Apnea-Related Cognitive and Mood Disorders","Regulatory Mechanisms of EGR2 and NLRP3 Inflammatory Pathways in Cognitive Impairment and Depressive-Anxiety-Like Behaviors Associated With Obstructive Sleep Apnea-Hypopnea Syndrome","Inclusion Criteria:\n\nChildren aged 2-18 years with obstructive snoring or sleep apnea features on initial ENT outpatient screening.\n\nAdults (\\>18 years) with suspected OSAS in a sleep or respiratory clinic, presenting with chronic snoring, witnessed apneas, or daytime sleepiness, and without severe chronic heart, liver, kidney failure, psychiatric disorders, or pregnancy.\n\nSigned written informed consent by the participant or their legal guardian. Not currently enrolled in any other registered clinical trial.\n\nExclusion Criteria:\n\nPresence of congenital craniofacial malformations. Severe heart, lung, liver, or kidney failure, or major neurological disease. Recent use of anti-inflammatory or other immunomodulatory medications. Current psychiatric disorder or pregnancy","5 Years",{"count":419,"type":22},"Obstructive sleep apnea-hypopnea syndrome (OSAS) is a common disorder in which repeated airway blockages during sleep lead to low oxygen levels, inflammation, and disrupted sleep. Many OSAS patients-both children and adults-experience problems with memory, attention, and mood, such as anxiety or depression. However, the exact molecular drivers of these brain changes are not fully understood.\n\nThis observational study will enroll:\n\nChildren (ages 2-18) and adults (\\>18 years) with OSAS, as well as age- and sex-matched healthy volunteers.\n\nClinical assessments: Children will undergo routine ENT examinations (including nasal endoscopy and X-rays); adults will have an overnight sleep study (polysomnography). All participants will complete questionnaires on sleepiness (e.g., ESS), mood (PHQ-9, GAD-7), and cognitive screening (MoCA for adults, age-appropriate scales for children).\n\nSample collection: A small blood draw (3 mL) and, when applicable (e.g., adults undergoing surgery), a tiny subcutaneous fat biopsy. Saliva samples will also be collected.\n\nLaboratory tests:\n\nMeasure expression levels of two key inflammatory pathway genes-EGR2 and NLRP3-in blood cells, saliva, and fat tissue using RNA sequencing, RT-qPCR, and Western Blot.\n\nCorrelate these molecular markers with sleep parameters (AHI, oximetry), cognitive scores, and mood scores.\n\nData analysis: Develop and validate machine-learning models that integrate data from multiple tissues to predict who is at highest risk for cognitive or mood disturbances.",[442,443,444],"Obstructive Sleep Apnea-Hypopnea Syndrome","Anxiety Disorders","Depressive Disorders","2025-08-07",{"date":447,"type":35},"2025-08-13",{"date":449,"type":35},"2025-07-01",{"date":451,"type":22},"2026-09-30",{"name":41,"class":42},{"id":454,"slug":455,"hasResults":12,"nctId":456,"briefTitle":457,"officialTitle":458,"acronym":459,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":123,"maxAge":304,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":67},"100579019","phase-4-the-effects-of-henagliflozin-on-glucose-fluctuation-and-immunosenescence-in-type-2-diabetes-patients-on-insulin-therapy-100579019","NCT06818851","The Effects of Henagliflozin on Glucose Fluctuation and Immunosenescence in Type 2 Diabetes Patients on Insulin Therapy","The Effects of Henagliflozin on glucOse fLuctuation and Immunosenescence in Type 2 Diabetes pAtients on Insulin therapY: a Multicenter, Randomized, Double-blind, Placebo-controlled Study (the HOLIDYA Study)","HOLIDYA","Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes mellitus (T2DM) for at least 6 months based on the 1999 WHO criteria.\n\n  * Age between 50 and 70 years at the time of signing the informed consent form (inclusive).\n  * Poor glycemic control despite treatment with basal insulin or insulin degludec\u002Faspart (with or without oral antidiabetic drugs) within the 3 months prior to screening.\n  * HbA1c level above 8%.\n  * BMI ≥ 20 kg\u002Fm².\n  * C-peptide levels within the normal reference range.\n  * Able to maintain stable dietary and exercise habits during the study.\n  * Capable of understanding the study procedures and methods, willing to strictly comply with the clinical trial protocol, and voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients considered by the investigator to have potential allergies to the components of the study drug or drugs of the same class.\n\n  * Use of SGLT2 inhibitors or GLP-1 receptor agonists within 3 months prior to screening.\n  * Adjustments to antidiabetic treatment regimens within 3 months prior to screening.\n  * Hospitalization due to acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery within 30 days prior to the screening visit.\n  * Volume depletion.\n  * Chronic (\\>2 weeks) systemic glucocorticoid therapy or use of glucocorticoids within 4 weeks prior to screening (except for topical, intraocular, intranasal, or inhaled administration).\n  * Pregnancy, lactation, or plans for pregnancy within the next 6 months.\n  * Persistently elevated serum transaminase levels (more than 3 times the upper limit of normal).\n  * Renal impairment (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 45 mL\u002Fmin\u002F1.73 m²).\n  * History of malignant tumors.\n  * Presence of acute complications (e.g., ketoacidosis, diabetic ketoacidosis, lactic acidosis, or hyperosmolar coma).\n  * Systemic autoimmune diseases, such as systemic lupus erythematosus.\n  * Clinically significant urinary tract infections and\u002For genital infections, or a history of recurrent urinary tract and\u002For genital infections.\n  * Any other factors deemed by the investigator to potentially affect the efficacy or safety evaluation of the study.\n  * Participation in other clinical trials and receipt of investigational drugs within 3 months prior to screening.",{"count":462,"type":22},64,[25],"The goal of this clinical trial is to learn if SGLT2 inhibitor Henggliflozin works to improve glucose variability in type 2 diabetes and if Henggliflozin can benefit immunosenescence.\n\nThe main questions it aims to answer are:\n\nDoes Henggliflozin as an add on treatment works to improve blood glucose fluctuation in type 2 diabetes? Does Henggliflozin has extra benefits like improve immunosenescence beyond hypoglycemic effects? Researchers will compare Henggliflozin to a placebo to see if Henggliflozin can improve glucose variability and immunosenescence.\n\nParticipants will:\n\nTake Henggliflozin or a placebo every day for 16 weeks. Receive weekly follow-up calls to guide them in adjusting their insulin doses. Return for an on-site visit at 4 weeks and 16 weeks. Take a continuous glucose monitoring (CGM) for 7 days at the Visit 1 and at the end of the study.",[466],"Diabetes Mellitus, Type 2",[468,469,470],"Sodium-glucose cotransporter 2","glycemic variability","immunosenescence","2025-07-16",{"date":473,"type":35},"2025-07-20",{"date":475,"type":35},"2025-07-14",{"date":477,"type":22},"2028-03-30",{"name":41,"class":42},{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":484,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":488,"conditions":489,"keywords":491,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":67},"100594238","effects-of-pha-hemoperfusion-plus-hemodialysis-on-protein-bound-uremic-toxins-100594238","NCT07016841","Effects of pHA Hemoperfusion Plus Hemodialysis on Protein-Bound Uremic Toxins","Effects of Conventional Hemodialysis Combined With pHA Hemoperfusion Therapy on Protein-Bound Uremic Toxins in Maintenance Hemodialysis Patients: A Single-Center, Prospective Cohort Study","Inclusion Criteria:\n\n1. Age ≥18 years, with no restriction on gender;\n2. Undergoing regular hemodialysis 3 times per week, 4 hours per session, and has received maintenance hemodialysis treatment for ≥3 months;\n3. Willing and able to receive treatment as per the protocol requirements, and has signed the informed consent form for subjects.\n\nExclusion Criteria:\n\n1. Patients receiving combined hemodialysis (HD) and peritoneal dialysis (PD) treatment;\n2. Patients with known allergy to hemoperfusion device materials, contraindications, or intolerance to the device;\n3. Patients with acute severe infection, severe cardiopulmonary insufficiency, severe cerebrovascular disease, severe bleeding tendency, or active bleeding;\n4. Patients with malignant tumors in the active stage or undergoing treatment for malignant tumors;\n5. Patients with a platelet count \\\u003C 60 × 10⁹\u002FL;\n6. Other conditions deemed unsuitable for enrollment in this study by the researchers.",{"count":487,"type":22},120,"This single-center, prospective cohort Study evaluates whether adding the pHA130 hemoperfusion cartridge to conventional hemodialysis (HD) or hemodiafiltration (HDF) more effectively reduces protein-bound uremic toxins-specifically indoxyl sulfate (IS) and p-cresyl sulfate (PCS)-in maintenance HD patients. Adults on thrice-weekly, 4-hour HD for at least three months are randomized to one of three arms: HD\u002FHDF alone; HD\u002FHDF plus biweekly pHA130 hemoperfusion; or HD\u002FHDF plus biweekly HA130 hemoperfusion. After a four-week washout, toxin levels are measured at baseline and again at Weeks 4, 12, and 24, with the primary endpoint being the reduction in IS and PCS at Week 24. Secondary endpoints include single-session toxin removal, middle-molecule clearance (β₂-microglobulin, PTH), patient-reported outcomes (itching, sleep, quality of life), and rates of hospitalization and mortality. Safety is closely monitored through adverse event reporting and consistent anticoagulation dosing. Findings will clarify the clinical value of pHA130 hemoperfusion for improving toxin clearance and guiding optimal dialysis strategies.",[490],"End Stage Renal Disease on Dialysis",[492,493],"Hemoadsorption","Hemodialysis","2025-06-10",{"date":496,"type":35},"2025-06-12",{"date":498,"type":35},"2025-05-12",{"date":500,"type":22},"2026-06-30",{"name":41,"class":42},{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":506,"acronym":4,"eligibilityCriteria":507,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":508,"enrollmentInfo":509,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":511,"conditions":512,"keywords":514,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":67},"100590567","a-study-on-the-correlation-between-oral-health-and-delirium-in-surgical-inpatients-100590567","NCT06969092","A Study on the Correlation Between Oral Health and Delirium in Surgical Inpatients","Inclusion Criteria:\n\n* Patients aged ≥18 years scheduled for elective cardiac or thoracic surgery requiring endotracheal intubation.\n\nPatients without consciousness impairment, able to cooperate with the investigation.\n\nPatients or their legal guardians informed about the study's purpose, methodology, and content, with signed informed consent forms.\n\nExclusion Criteria:\n\n* Patients with pre-existing oral conditions (e.g., xerostomia, oral mucosal lesions) prior to mechanical ventilation.\n\nPatients with a history of radiotherapy, chemotherapy, or corticosteroid use before surgery.\n\nPatients experiencing intraoperative mortality.","90 Years",{"count":510,"type":22},550,"Delirium is a clinical syndrome characterized by acute attention deficits, altered consciousness, and fluctuating cognitive dysfunction, typically triggered by multifactorial causes such as physical illness, medication use, or postoperative stress . As the most common complication in hospitalized patients, delirium is highly prevalent among elderly surgical populations, with postoperative delirium (POD) occurring in 7.5%-27.5% of cases, and rates rising to 50%-70% in intensive care unit (ICU) patients . Its onset is closely associated with poor prognoses, including long-term postoperative cognitive decline , increased mortality, prolonged hospitalization, and elevated healthcare costs (annual costs in the United States ranging from 38billionto152 billion) . Early prevention and screening of POD are therefore critical to improving patient outcomes and reducing healthcare burdens.\n\nSurgical patients' oral health issues exhibit multifactorial pathogenesis: intrinsic factors (e.g., age-related tooth loss, malnutrition-induced mucosal repair impairment, and chewing dysfunction due to reduced skeletal muscle mass) and iatrogenic factors (e.g., endotracheal intubation trauma, salivary secretion suppression from analgesics, and inadequate perioperative oral care). Poor oral health in hospitalized patients is often attributable to aging, physical dependence, cognitive decline, malnutrition, low skeletal muscle mass\u002Fstrength, and comorbidities. The recently proposed concept of \"Oral Frailty\"-a progressive decline in oral structure and function-strongly predicts physical frailty, dysphagia, malnutrition, long-term care needs, and mortality in community-dwelling older adults\n\nThe impact of oral health on cognitive function may involve three pathways :\n\nMechanical pathway: Tooth loss disrupts masticatory motor function, reduces cerebral blood flow, and diminishes afferent stimulation from peripheral receptors (e.g., periodontal ligaments), leading to weakened neural connectivity and regional brain atrophy.\n\nNeurodegenerative pathway: Tooth loss accelerates neuronal damage via apoptosis and mitophagy, increasing amyloid-beta deposition in the brain.\n\nInflammatory\u002Fmetabolic pathway: Systemic inflammation, metabolic dysregulation, microbial-gut-brain axis interactions, and activation of microglia\u002Fastrocytes drive neuroinflammatory cascades in the central nervous system.\n\nGiven these connections, oral frailty may act as an independent risk factor distinct from general frailty and a potential contributor to POD. These findings suggest that oral frailty could serve as a unique biomarker for perioperative neurocognitive disorders, mediating their pathogenesis. Systematic investigation into the spatiotemporal relationship and mechanisms linking oral health to POD in surgical patients holds significant clinical value for developing multimodal prevention strategies.",[513],"Oral Health",[513,515,516,517,518,519,520],"Oral Frailty","Surgical","Surgery","Delirium","Endotracheal Intubation","Cognitive Function","2025-05-06",{"date":523,"type":35},"2025-05-13",{"date":525,"type":22},"2025-05-25",{"date":527,"type":22},"2026-03-25",{"name":41,"class":42},{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":542,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":67},"100588028","a-prpct-to-assess-the-efficacy--safety-of-chronic-pain-rehab-training-software-for-alleviating-chronic-secondary-musculoskeletal-pain-100588028","NCT06936059","A PRPCT to Assess the Efficacy & Safety of Chronic Pain Rehab Training Software for Alleviating Chronic Secondary Musculoskeletal Pain","A Prospective, Randomized, Parallel-controlled Clinical Trial to Evaluate the Effectiveness and Safety of Chronic Pain Rehabilitation Training Software in Assisting in the Relief of Chronic Secondary Musculoskeletal Pain","Inclusion Criteria:\n\n* Males and females ≥18 years old.\n* Average pain intensity≥4 on a 0-10 numerical rating scale (NRS) in the past 24 hours.\n* Be able to communicate in Chinese.\n* Be able to read and write Chinese.\n* Willing to comply with study procedures and restrictions.\n* Willing and able to sign informed consent.\n\nExclusion Criteria:\n\n* Shingles on the eyes, ears, head, face, or hands.\n* Trigeminal neuralgia.\n* Severe vision impairment. (Patients with clear vision wearing glasses or contact lenses are allowed)\n* Severe hearing impairment.\n* Disease or medical condition predisposing to nausea or dizziness, such as insufficient blood supply to the brain, vestibular dysfunction,cholecystitis, etc.\n* History of severe motion sickness.\n* Injury to eyes, ears, face, or neck that impedes comfortable use of mixed reality.\n* Injury or dysfunction of hands or upper limbs that impedes comfortable use of mixed reality.\n* Diagnosis of cognitive impairment, epilepsy, dementia, migraines or other neurological diseases that may prevent the use of mixed reality.\n* History of mental illness, including depression, generalized anxiety disorder, schizophrenia, etc.\n* Females currently pregnant.\n* Current or completion of participation within 4 weeks before screening in any interventional clinical study\n* Patients whom the investigator considers not suitable to participate in this study.",{"count":537,"type":22},80,[55],"A prospective, randomized, parallel-controlled clinical trial to evaluate the effectiveness and safety of chronic pain rehabilitation training software in assisting in the relief of chronic secondary musculoskeletal pain",[541],"Chronic Pain",[543,544,545,546,547],"pain","Visual Pain Score","rehab training software","anxious","depressed","2025-04-13",{"date":550,"type":35},"2025-04-20",{"date":552,"type":22},"2025-11-12",{"date":554,"type":22},"2026-11-12",{"name":41,"class":42},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":562,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":564,"conditions":565,"keywords":566,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":576},"100584128","construction-of-a-multi-center-clinical-research-collaboration-network-for-children-with-congenital-heart-disease-in-china-100584128","NCT06885307","Construction of a Multi-center Clinical Research Collaboration Network for Children with Congenital Heart Disease in China","Inclusion Criteria:\n\n1. Age 0-18 years, regardless of gender;\n2. Patients diagnosed with congenital heart disease confirmed by cardiac ultrasound examination;\n\nExclusion Criteria:\n\nNone",{"count":563,"type":22},35000,"This project intends to unite the representatives of typical congenital heart disease hospitals in various provinces and cities across the country to jointly establish a multi-center clinical research collaboration network for children with congenital heart disease in China, establish a platform and mechanism for the collection and sharing of data on children with congenital heart disease in China, and create a real-world public database of children with congenital heart disease in China that benchmarks the international level, so as to provide a solid data foundation for high-quality research on children with congenital heart disease in China.",[217],[217,567],"Database","2025-03-19",{"date":570,"type":35},"2025-03-20",{"date":572,"type":35},"2019-06-01",{"date":574,"type":22},"2025-12-30",{"name":41,"class":42},6,{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":581,"acronym":4,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":326,"maxAge":18,"enrollmentInfo":583,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":584,"conditions":585,"keywords":591,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":595,"lastUpdatePostDateStruct":596,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":4},"100579326","accurate-diagnosis-and-grading-of-pediatric-solid-tumors-based-on-pathological-large-models-100579326","NCT06822842","Accurate Diagnosis and Grading of Pediatric Solid Tumors Based on Pathological Large Models","Inclusion Criteria:\n\n1. Neuroblastoma (NB): For newly diagnosed patients with NB aged 0-18 years, the diagnosis criteria are one of the following two items: (1) the patient's tumor tissue has obtained a positive pathological diagnosis under the light microscope; (2) Bone marrow biopsy or aspiration revealed characteristic neuroblastoma cells, which were small round cells, arranged in a nested or chrysanthemum clump or positive staining for anti-GD2 antibodies, and accompanied by an increase in urinary vanillylmandelic acid (VMA) and an increase in blood neuron-specific enolase (NSE).\n2. Wilms tumor (nephroblastoma): patients aged 0-18 years old who have been diagnosed with Wilms tumor by histopathology.\n3. Hepatoblastoma (HB): Patients aged 0-18 years who have been diagnosed with hepatoblastoma by histopathology.\n4. Medulloblastoma (MB): Patients aged 0-18 years with a confirmed histopathological diagnosis of medulloblastoma.\n5. rhabdomyosarcoma (RMS): patients aged 0-18 years old who have been diagnosed with medulloblastoma by histopathology.\n\nExclusion Criteria:\n\n1. The patient's medical record and treatment follow-up information are incomplete; HE is not stained or faded\n2. Those who have 2 or more types of tumors at the same time;\n3. Those who do not meet the enrollment criteria.\n4. Tumor subtype with less than 3 WSI images",{"count":398,"type":22},"Pediatric malignancies are the second leading cause of death in the pediatric population, with solid tumors accounting for approximately 60% of all pediatric malignancies. The pathological diagnosis of pediatric solid tumors is highly complex and specialized, because of its diverse tissue morphology, rare tumor subtypes and lack of labeling data, the traditional pathological diagnosis relies on the experience of senior pathologists, but in actual clinical practice, due to the lack of expert resources and inconsistent diagnostic standards, more efficient and accurate auxiliary diagnostic tools are urgently needed. In this study, we aim to construct a multimodal dataset by collecting high-quality pathological images and pathological diagnosis results of pediatric solid tumors (neuroblastoma, medulloblastoma, Wilms tumor, hepatoblastoma, rhabdomyosarcoma, etc.), and introduce medical knowledge enhancement strategies on this basis, and improve the medical reasoning ability and adaptability to fine-grained pathological tasks by injecting domain knowledge (such as molecular characteristics of tumors, pathological grading standards, diagnostic rules, etc.) into the model. Through the model, the representation space of images and texts is unified, and diversified diagnostic tasks of pediatric solid tumors such as tumor region segmentation, cancer detection, and tumor subtype identification are realized, providing intelligent support for the accurate diagnosis and personalized treatment of pediatric solid tumors.",[586,587,588,589,590],"Neuroblastoma","Medulloblastoma","Wilms Tumor","Hepatoblastoma","Rhabdomyosarcoma",[592,593,594],"Machine learning","Diagnosis","Pathological classification","2025-02-06",{"date":597,"type":35},"2025-02-12",{"date":599,"type":22},"2025-02-01",{"date":601,"type":22},"2025-04-30",{"name":41,"class":42},""]